ACE — Ascelia Pharma AB Income Statement
0.000.00%
Last trade - 00:00
- SEK459.60m
- SEK438.81m
2019 June 30th | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 37.4 | 93.4 | 138 | 147 | 111 |
Operating Profit | -37.4 | -93.4 | -138 | -147 | -111 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -37.6 | -99.7 | -130 | -133 | -110 |
Provision for Income Taxes | |||||
Net Income After Taxes | -37.1 | -98.7 | -126 | -131 | -109 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -37.1 | -98.7 | -126 | -131 | -109 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -37.1 | -98.7 | -126 | -131 | -109 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.16 | -3.76 | -3.82 | -3.77 | -3.24 |
Dividends per Share |